AlzeCure Pharma's preclinical TrkA-NAM project for osteoarthritis pain accepted for IASP 2024 World Congress on Pain.

AlzeCure Pharma, a Swedish pharmaceutical company specializing in CNS diseases, announced acceptance of an abstract for its preclinical TrkA-NAM project targeting osteoarthritis pain and other severe pain conditions at the IASP 2024 World Congress on Pain in Amsterdam. The abstract, titled "Pharmacological Effects of ACD137, a Potent and Selective Negative Allosteric Modulator of TrkA," will be presented by project leader Pontus Forsell.